Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Failed NDIs, FDA's Opioid Concerns Don't Stop Kratom Supplement Sales

Aug 17 2018

• By Malcolm Spicer

Related Content

FDA Turns Kratom's Future In US Dietary Supplement Market Into History

Nov 15 2017

FDA Waves Stop Sign At Kratom Product Launch After Failed NDI Notification

Feb 27 2018

FDA's Kratom Campaign Turns To Firms Destroying Inventory, Recalling Products

Feb 21 2018

Kratom Group Contests FDA's Opioid Finding, Requests Joint Meeting With NIDA

Aug 16 2018

Salmonella In Kratom, Like Use Of The Herb, Exceeds FDA Expectations

Jul 02 2018

FDA's Opioid Label For Kratom Called Misbranding By Marketers

Feb 07 2018

Additional Topics

United States Dietary Supplements Advertising, Marketing & Sales Regulation Consumer

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window